NasdaqHealth CareHealth Care ServicesS&P SmallCap 600
$7.34
-0.22 (-2.91%)
Close of Nov 06, 2026 · end-of-day data
ALHC 8-K filings in 2024
Every material Form 8-K Alignment Healthcare filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Alignment Healthcare completed the sale of $330 million of 4.25% convertible senior notes due 2029 and reported net cash proceeds of approximately $321.05 million. The company used the proceeds to repay in full the term loans under its Oxford Loan Agreement, which had $215 million of principal outstanding, and the agreement was terminated. The notes can convert into common stock, so the financing changes the company's debt structure and could affect shareholders if conversion occurs.
$330 million aggregate principal of 4.25% Convertible Senior Notes due 2029, issued under an indenture dated November 22, 2024, with U.S. Bank Trust Company, National Association, as trustee
Net cash proceeds of approximately $321.05 million after fees, discounts and estimated expenses
Oxford term loans, which carried interest at SOFR + 6.5%, were repaid in full on November 22, 2024, with $215 million outstanding as of that date, and all liens were released
Notes were sold to institutional accredited and qualified institutional buyers in a private offering exempt from Securities Act registration
Alignment Healthcare entered into subscription agreements on November 14, 2024 to privately issue $330 million of 4.25% convertible senior notes due November 15, 2029, with closing expected on November 22, 2024. The company expects net proceeds of about $321.05 million, which it intends to use to repay its existing term loan, which bears interest at SOFR + 6.5%, and for general corporate purposes. The notes are convertible into common stock at an initial price of about $16.04 per share, a 25% premium to the November 14, 2024 closing price, so conversion could add shares outstanding.
Principal: $330 million of 4.25% convertible senior notes due November 15, 2029, sold in a private placement
Expected net cash proceeds: about $321.05 million, to repay the term loan (SOFR + 6.5%) and for general corporate purposes
Initial conversion price: about $16.04 per share, a 25% premium to the November 14, 2024 closing price
Expected closing: November 22, 2024, subject to customary closing conditions
Alignment Healthcare reported third-quarter 2024 results, with total revenue of $692.4 million, up 51.6% from a year earlier, and a net loss of $26.4 million, narrowed from $35.1 million. The company raised its full-year 2024 revenue and membership guidance and narrowed its adjusted gross profit and adjusted EBITDA guidance.
Q3 total revenue was $692.4 million, up from $456.7 million in the year-earlier quarter.
Net loss was $26.4 million, or $(0.14) per share, versus a net loss of $35.1 million, or $(0.19) per share, a year earlier.
Health plan membership was about 182,300 at quarter end, up 57.7% year over year.
Full-year 2024 revenue guidance is $2.665 billion to $2.680 billion; full-year adjusted EBITDA guidance is a loss of $10 million to income of $5 million.
Directors Jeffrey Margolis and Thomas Carella resigned from the board effective immediately, with the company saying the resignations were not due to any disagreement. Mr. Margolis also entered a consulting agreement with the company's primary operating subsidiary, and the board cut its authorized size and reshuffled committee leadership to keep Nasdaq listing compliance.
Jeffrey Margolis and Thomas Carella resigned from the board, notified August 13, 2024 and August 14, 2024, respectively
Board authorized size reduced from eleven to nine directors; Margaret McCarthy reclassified from Class I to Class III
Margolis consulting agreement effective August 13, 2024, with a one-time payment of $18,333 and monthly retainers ranging from $9,167 to $21,667 through June 2026
Alignment Healthcare reported second-quarter 2024 revenue of $681.3 million, up 47.3% from a year earlier, and a net loss of $24.0 million, narrowed from $28.5 million. The company raised its year-end membership and revenue guidance and kept its full-year adjusted gross profit and adjusted EBITDA guidance unchanged, which shows the larger revenue base is also producing a smaller loss.
Total revenue was $681.3 million, up 47.3% year over year, and health plan membership was about 175,100, up 56.1%.
Adjusted EBITDA was $6.0 million, compared with a loss of $2.1 million a year earlier; net loss was $24.0 million versus $28.5 million.
Full-year 2024 revenue guidance was raised to $2.61 billion to $2.64 billion, and year-end membership guidance was raised to 178,000 to 180,000.
Full-year adjusted gross profit ($280 million to $310 million) and adjusted EBITDA (–$12 million to $12 million) guidance was maintained.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Alignment Healthcare filing is on SEC EDGAR ↗. 8-K briefs of other companies →